Cargando…

Profile of patients with gastrointestinal stromal tumors (GIST)

BACKGROUND: There is an improvement on the GIST treatment in last decade due to biomolecular research and adjuvant therapy with tyrosine kinases inibitors. However, both modalities of treatment rarely are available in Brazilian public hospital. AIM: Evaluate GIST patients profile in public oncologic...

Descripción completa

Detalles Bibliográficos
Autores principales: PRACUCHO, Eduardo Marcucci, LOPES, Luiz Roberto, ZANATTO, Renato Morato, TOMAL, Karla Thaisa, PASSERI, Celso Roberto, MOLAN, Joel Roberto Sagioro, PRADO, Ari de Almeida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Colégio Brasileiro de Cirurgia Digestiva 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737335/
https://www.ncbi.nlm.nih.gov/pubmed/26176250
http://dx.doi.org/10.1590/S0102-67202015000200010
_version_ 1782413466338852864
author PRACUCHO, Eduardo Marcucci
LOPES, Luiz Roberto
ZANATTO, Renato Morato
TOMAL, Karla Thaisa
PASSERI, Celso Roberto
MOLAN, Joel Roberto Sagioro
PRADO, Ari de Almeida
author_facet PRACUCHO, Eduardo Marcucci
LOPES, Luiz Roberto
ZANATTO, Renato Morato
TOMAL, Karla Thaisa
PASSERI, Celso Roberto
MOLAN, Joel Roberto Sagioro
PRADO, Ari de Almeida
author_sort PRACUCHO, Eduardo Marcucci
collection PubMed
description BACKGROUND: There is an improvement on the GIST treatment in last decade due to biomolecular research and adjuvant therapy with tyrosine kinases inibitors. However, both modalities of treatment rarely are available in Brazilian public hospital. AIM: Evaluate GIST patients profile in public oncologic hospital. METHODS: A retrospective study was made on patients with GIST diagnosed and treated between 2001 and 2013. RESULTS: Sixty-nine patients were included, mean age 59 years with slight predominance in females (51%). The main symptom was abdominal pain associated with incidental imaging finding. The occurrence of other associated neoplasm was in 28.8% of cases. The positivity of CD117 was 97.1%. The most frequent location was the stomach in 55.1% of cases. The R0 resection was possible in 63.8% and the recurrence rate was 20.3 %, with liver and peritoneum the main affected sites. Overall survival in the whole sample was 71%. Free survival rate of disease was 64%. The use of imatinib was limited to patients with residual disease (unresectable disease, R2 and R1 resection), metastatic disease or recurrence. CONCLUSION: In order to improve GIST treatment is necessary to add the biomolecular analysis to risk stratification. However, for this to occur, incentive in biomolecular research is required, to increase the possibility of patient survival.
format Online
Article
Text
id pubmed-4737335
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Colégio Brasileiro de Cirurgia Digestiva
record_format MEDLINE/PubMed
spelling pubmed-47373352016-02-24 Profile of patients with gastrointestinal stromal tumors (GIST) PRACUCHO, Eduardo Marcucci LOPES, Luiz Roberto ZANATTO, Renato Morato TOMAL, Karla Thaisa PASSERI, Celso Roberto MOLAN, Joel Roberto Sagioro PRADO, Ari de Almeida Arq Bras Cir Dig Original Article BACKGROUND: There is an improvement on the GIST treatment in last decade due to biomolecular research and adjuvant therapy with tyrosine kinases inibitors. However, both modalities of treatment rarely are available in Brazilian public hospital. AIM: Evaluate GIST patients profile in public oncologic hospital. METHODS: A retrospective study was made on patients with GIST diagnosed and treated between 2001 and 2013. RESULTS: Sixty-nine patients were included, mean age 59 years with slight predominance in females (51%). The main symptom was abdominal pain associated with incidental imaging finding. The occurrence of other associated neoplasm was in 28.8% of cases. The positivity of CD117 was 97.1%. The most frequent location was the stomach in 55.1% of cases. The R0 resection was possible in 63.8% and the recurrence rate was 20.3 %, with liver and peritoneum the main affected sites. Overall survival in the whole sample was 71%. Free survival rate of disease was 64%. The use of imatinib was limited to patients with residual disease (unresectable disease, R2 and R1 resection), metastatic disease or recurrence. CONCLUSION: In order to improve GIST treatment is necessary to add the biomolecular analysis to risk stratification. However, for this to occur, incentive in biomolecular research is required, to increase the possibility of patient survival. Colégio Brasileiro de Cirurgia Digestiva 2015 /pmc/articles/PMC4737335/ /pubmed/26176250 http://dx.doi.org/10.1590/S0102-67202015000200010 Text en http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
PRACUCHO, Eduardo Marcucci
LOPES, Luiz Roberto
ZANATTO, Renato Morato
TOMAL, Karla Thaisa
PASSERI, Celso Roberto
MOLAN, Joel Roberto Sagioro
PRADO, Ari de Almeida
Profile of patients with gastrointestinal stromal tumors (GIST)
title Profile of patients with gastrointestinal stromal tumors (GIST)
title_full Profile of patients with gastrointestinal stromal tumors (GIST)
title_fullStr Profile of patients with gastrointestinal stromal tumors (GIST)
title_full_unstemmed Profile of patients with gastrointestinal stromal tumors (GIST)
title_short Profile of patients with gastrointestinal stromal tumors (GIST)
title_sort profile of patients with gastrointestinal stromal tumors (gist)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737335/
https://www.ncbi.nlm.nih.gov/pubmed/26176250
http://dx.doi.org/10.1590/S0102-67202015000200010
work_keys_str_mv AT pracuchoeduardomarcucci profileofpatientswithgastrointestinalstromaltumorsgist
AT lopesluizroberto profileofpatientswithgastrointestinalstromaltumorsgist
AT zanattorenatomorato profileofpatientswithgastrointestinalstromaltumorsgist
AT tomalkarlathaisa profileofpatientswithgastrointestinalstromaltumorsgist
AT passericelsoroberto profileofpatientswithgastrointestinalstromaltumorsgist
AT molanjoelrobertosagioro profileofpatientswithgastrointestinalstromaltumorsgist
AT pradoaridealmeida profileofpatientswithgastrointestinalstromaltumorsgist